News

Alzheimer's Prevention Initiative's discusses a genetic counseling and disclosure model for its Generation Program.

How the use of M&S in cancer trials from the outset can help address those critical “what if?” scenarios and accelerate oncology drug development.

The region is significantly underrepresented in clinical development activity targeting childhood cancer.

Insights on the challenges, activity, and motives in merging bridging research and clinical care.

Site models that meet patient needs at the site level.

Partnership focuses on integrating research into the care continuum.

Case study highlights a new patient-centric enrollment model that uses a data-driven approach to identify qualified patients first.

Reexamining traditional cycle-time reduction strategies is critical for sponsors, CROs, and sites.

The relationship between European patients and drug developers has gone through many twists and turns over the years-and is still seeking equilibrium.

Comprehensive market landscaping includes disparate data sets from primary and secondary sources and is a time-consuming process that requires domain expertise and commitment.

Michael Sydes outlines some strategies that CRA's can use to maintain good clinical practices.

This article will address concerns and look at how the pragmatic implementation of surveys in today’s clinical trials can provide valuable insight into patient satisfaction levels, motivators, likelihood to follow study requirements and information retention.

As part of efforts to speed patient access to effective new therapies, FDA is rolling out policies designed to streamline drug development, particularly for new cancer therapies to treat life-threatening conditions.

Updated employee announcements, business news, awards, and recognition in the industry today.